US-based privately-held therapeutic antibody firm AnaptysBio has commenced an antibody development program with Momenta Pharmaceuticals, focused on the development of new antibodies against a therapeutically relevant target. Both the ...
Therapeutic antibodies developer AnaptysBio has expanded its proprietary immunotherapy antibody portfolio to add multiple new combination therapies. The company developed a proprietary anti-PD-1 antibody, called ANB011, with key ...
Tags: AnaptysBio, Antibody Portfolio